Important Information about Young Donor Plasma Infusions for Profit
regulatory notice · 2019
LINK
SUMMARY
FDA safety communication (19 February 2019, attributed to then-Commissioner Scott Gottlieb and CBER director Peter Marks) warning that infusions of plasma from young donors have no proven clinical benefit for aging, memory loss, dementia, or several other conditions for which such infusions were being marketed, and that plasma infusion carries infectious, allergic, respiratory, and cardiovascular risks. The statement predates and was not directed at Bryan Johnson specifically, but describes exactly the category of intervention (paid young-donor plasma infusion marketed against aging) that Johnson's 2023 self-experiment used. Regulator-tier source under the sourced-critique standard. Direct WebFetch access to the FDA page returned HTTP 403 in this authoring session (also tried via web.archive.org, also blocked); the date and content above are confirmed via an independent search-engine snippet quoting the FDA page directly and are used here only in paraphrase, never as a verbatim quotation, so no verify-quotes block is required.
NOTES
The FDA’s 2019 statement is cited as background regulatory context for the plasma-exchange claim in this case, not as a specific finding about Johnson. It establishes that the regulator considers the entire category of paid young-donor plasma infusion for anti-aging purposes to be without proven clinical benefit and carrying disclosed risks, which independently corroborates Johnson’s own July 2023 conclusion that he observed no benefit.